J. David Enloe Jr. Net Worth

The estimated Net Worth of J David Jr Enloe is at least $1.35 Milion dollars as of 15 March 2022. Mr Enloe owns over 512 units of Recro Pharma Inc stock worth over $1,096,997 and over the last 4 years he sold REPH stock worth over $0. In addition, he makes $255,526 as Pres a CEO & Director at Recro Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Jr REPH stock SEC Form 4 insiders trading

Mr has made over 5 trades of the Recro Pharma Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 512 units of REPH stock worth $1,004 on 15 March 2022.

The largest trade he's ever made was buying 1,725 units of Recro Pharma Inc stock on 12 November 2021 worth over $2,898. On average, Mr trades about 575 units every 18 days since 2020. As of 15 March 2022 he still owns at least 524,879 units of Recro Pharma Inc stock.

You can see the complete history of Mr Enloe stock trades at the bottom of the page.

Mr. J. David Enloe Jr. biography

J. David Enloe Jr. is the Pres, CEO & Director at Recro Pharma Inc.

What is the salary of Mr Jr?

As the Pres a CEO & Director of Recro Pharma Inc, the total compensation of Mr Jr at Recro Pharma Inc is $255,526. There are 8 executives at Recro Pharma Inc getting paid more, with Geraldine Henwood having the highest compensation of $4,622,980.

How old is Mr Jr?

Mr Jr is 57, he's been the Pres a CEO & Director of Recro Pharma Inc since . There are 5 older and 4 younger executives at Recro Pharma Inc. The oldest executive at Recro Pharma Inc is Winston Churchill, 79, who is the Independent Director.

What's Mr Jr's mailing address?

J's mailing address filed with the SEC is C/O RECRO PHARMA, INC., 1 E. UWCHLAN AVE, SUITE 112, EXTON, PA, 19341.

Insiders trading at Recro Pharma Inc

Over the last 11 years, insiders at Recro Pharma Inc have traded over $25,533,136 worth of Recro Pharma Inc stock and bought 3,055,820 units worth $22,429,197 . The most active insiders traders include Healthcare Master Fund Ltd ..., Investment Company, Inc. Awm a James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of $151,953. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth $1,004.

What does Recro Pharma Inc do?

Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

Complete history of Mr Enloe stock trades at Recro Pharma Inc

Recro Pharma Inc executives and stock owners

Recro Pharma Inc executives and other stock owners filed with the SEC include:

• Geraldine Henwood,
  President, Chief Executive Officer, Director
• Ryan Lake,
  Chief Financial Officer
• William Ashton,
  Independent Director
• Wayne Weisman,
  Independent Chairman of the Board
• Winston Churchill,
  Independent Director
• Michael Berelowitz,
  Independent Director
• Ryan D. Lake,
  Chief Financial Officer
• Bryan Reasons,
  Independent Director
• J. David Enloe Jr.,
  Pres, CEO & Director
• Argot Partners,
  IR Contact Officer
• Tim Bourque,
  VP of Operations & Site Head of San Diego
• David Smithwick B.S.,
  VP of Operations & Site Head of Gainesville
• Richard Sidwell Ph.D.,
  VP & Chief Scientific Officer
• Marshall Rizzo M.B.A.,
  Sr. VP & GM
• Randall J. Mack,
  Sr. VP of Devel.
• Erica Raether M.A.,
  VP of People, Culture & ESG
• William Hirschman,
  VP of Sales & Marketing
• Matthew McKendry,
  Director of Accounting
• Laura L. Parks,
  Director
• Karen Flynn,
  Director
• Vitalife Partners Ii Lp Scp,
  10% owner
• Donna Nichols,
  CAO/Controller
• Stewart Mc Callum,
  Chief Medical Officer
• Randall Mack,
  Senior VP, Development
• Fred Graff,
  Chief Commercial Officer
• Capital Management, Llc Sto...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Vitalife Partners (Israel) ...,
  10% owner
• Alfred Altomari,
  Director
• Healthcare Master Fund Ltd ...,
  
• Diane Myers,
  Senior VP-Reg./Quality
• Jyrki Mattila,
  Executive VP, Business Dev.
• Michael Celano,
  Chief Financial Officer
• Arnaud Ajdler,
  Director
• Abraham Ludomirski,
  Director
• Charles Garner,
  CFO and Chief Business Officer
• J David Jr Enloe,
  Chief Executive Officer
• James Charles Miller,
  Director
• Investment Company, Inc. Awm,
  10% owner